Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.44
-0.26 (-3.05%)
Apr 29, 2026, 1:05 PM EDT - Market open
Kyverna Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cash & Equivalents | 124.09 | 96.62 | 34.65 | 37.74 | 76.07 |
| Short-Term Investments | 155.16 | 189.36 | 22.9 | 13.59 | - |
| Cash & Short-Term Investments | 279.25 | 285.98 | 57.54 | 51.32 | 76.07 |
| Cash Growth | -2.35% | 396.98% | 12.12% | -32.53% | - |
| Prepaid Expenses | 3.6 | 4.62 | 3.12 | 1.93 | 1.02 |
| Other Current Assets | 0.1 | - | - | - | - |
| Total Current Assets | 282.95 | 290.6 | 60.66 | 53.25 | 77.09 |
| Property, Plant & Equipment | 5.42 | 10.66 | 10.61 | 12.44 | 7.81 |
| Long-Term Deferred Charges | - | - | 2.5 | - | - |
| Other Long-Term Assets | 5.45 | 3.39 | 1.42 | 1.23 | 0.59 |
| Total Assets | 293.83 | 304.65 | 75.2 | 66.92 | 85.49 |
| Accounts Payable | 5.31 | 4.62 | 4.36 | 1.45 | 0.77 |
| Accrued Expenses | 27.21 | 25.19 | 9.06 | 7.66 | 7.77 |
| Current Portion of Leases | 3.97 | 3.94 | 2.92 | 2.28 | 0.81 |
| Current Unearned Revenue | - | - | - | - | 6 |
| Other Current Liabilities | - | - | 3.52 | 0.57 | 0.58 |
| Total Current Liabilities | 36.49 | 33.76 | 19.86 | 11.95 | 15.93 |
| Long-Term Debt | 24.74 | - | - | - | - |
| Long-Term Leases | 0.32 | 4.3 | 6.16 | 8.29 | 4.74 |
| Long-Term Unearned Revenue | - | - | - | - | 1.03 |
| Other Long-Term Liabilities | - | - | - | 0.01 | 1.33 |
| Total Liabilities | 61.55 | 38.06 | 26.02 | 20.25 | 23.02 |
| Common Stock | 0 | - | - | - | - |
| Additional Paid-In Capital | 657.01 | 530 | 4.64 | 1.71 | 0.53 |
| Retained Earnings | -424.83 | -263.52 | -136.04 | -75.68 | -46.78 |
| Comprehensive Income & Other | 0.1 | 0.11 | 0 | -0.03 | - |
| Total Common Equity | 232.28 | 266.59 | -131.4 | -74 | -46.25 |
| Shareholders' Equity | 232.28 | 266.59 | 49.18 | 46.68 | 62.47 |
| Total Liabilities & Equity | 293.83 | 304.65 | 75.2 | 66.92 | 85.49 |
| Total Debt | 29.03 | 8.24 | 9.08 | 10.56 | 5.56 |
| Net Cash (Debt) | 250.22 | 277.74 | 48.46 | 40.76 | 70.51 |
| Net Cash Growth | -9.91% | 473.08% | 18.91% | -42.20% | - |
| Net Cash Per Share | 5.65 | 7.25 | 71.95 | 89.48 | 265.19 |
| Filing Date Shares Outstanding | 60.46 | 43.21 | 43.12 | 0.55 | 0.27 |
| Total Common Shares Outstanding | 60.39 | 43.21 | 1.25 | 0.55 | 0.27 |
| Working Capital | 246.47 | 256.85 | 40.81 | 41.3 | 61.16 |
| Book Value Per Share | 3.85 | 6.17 | -105.11 | -133.91 | -173.96 |
| Tangible Book Value | 232.28 | 266.59 | -131.4 | -74 | -46.25 |
| Tangible Book Value Per Share | 3.85 | 6.17 | -105.11 | -133.91 | -173.96 |
| Machinery | 4.36 | 6.2 | 4.17 | 3.74 | 3.35 |
| Leasehold Improvements | 0.94 | 0.82 | 0.65 | 0.46 | 0.08 |
Source: S&P Capital IQ. Standard template. Financial Sources.